Novo Hiring New Reps, Now They Need Something To Sell

Feb 6 2014, 1:43pm CST | by

Novo Hiring New Reps, Now They Need Something To Sell

In news that should come as a surprise to no one, it looks like Roche Diabetes Care is about to undergo yet another restructuring, which is really a nice way of saying more layoffs are coming. Perhaps the real news here is that Roche actually has anyone left in the unit to layoff. Like everyone else in conventional blood glucose monitoring, Roche has cut costs to the bone as they desperately try and find a buyer for this beleaguered unit.

Compare this news to an article that appeared in Fierce PharmaMarketing which stated:

“When we hear about companies actually hiring reps, that’s news. Given the thousands of sales layoffs over the past several years–and recruiting focused on emerging markets, especially China–staffing up in the U.S. or Europe is out of the ordinary. When that hiring isn’t about a new drug launch, we hardly know what to make of it.

That’s just what Novo Nordisk has been doing: hiring reps by the hundred in the U.S. First, it was in anticipation of the Tresiba launch that didn’t happen in 2013, but last fall, another 350 joined the company. Couple that with 120 new nurse educators, and the Danish drugmaker has expanded its field force by almost 15%.”

Granted the diabetes drug market is not as bad as the diabetes device market, but it won’t be long before it suffers the same fate, which makes this decision by Novo Nordisk (NVO) even stranger and not just from a cost perspective. It’s a well-known fact that the fewer and fewer physicians are actually seeing sales reps. It’s also true that while the physician would like to have control over which drugs they prescribe increasingly this decision is being taken away from the physician and put in the hands of the patients insurance company.

Although pharma reps hate to hear this, the reality is their job function can be easily and more cost effectively performed by an automated or virtual system. This is increasingly true with diabetes drugs which are filled with me-too copycats that all do basically the same thing pretty much the same way. The days of pharma reps sitting with physicians reviewing the latest study data are over, the simple fact is if a physician wants information on any drug the fastest, easiest way to get it is to surf the net. Add in the fact that either by law or by cost concerns also over are the days when reps can leave behind drug samples.

Novo’s decision to continue to add reps while the competition is moving in the exact opposite direction would make sense if they actually had something new to sell. Yet with Tresiba delayed at the FDA indefinitely we can’t quite figure out what exactly these people will be doing. This is not like the old days when a company could put an army of reps into the field and see an almost impact on sales growth. Novo already has a well-established and well known product line. So again just what new stories can these reps, the lucky few who actually get to sit down with a physician, say.

Lastly there is the cost issue which is a major issue when one considers that pricing pressure continues to intensify. This move to add reps makes me believe that old habits die hard at Novo as they continue to believe that they will receive premium pricing for the products they make. There continued pursuit to have Tresiba approved in the U.S. is another example of this.

While the FDA is being overly cautious with Tresiba, the fact is even if the drug does eventually make it to market it will have a tough time given it’s likely a generic version of Lantus will be available which will drive prices even lower.

Years ago I warned everyone that the BGM market was transforming itself from a medical device to commodity market where price trumps performance. Unfortunately for BGM companies this prediction came true and as a result they are watching a once prosperous business sink into oblivion. Unable to divest themselves of these units it makes perfect sense they would cut costs to the bone and get whatever they can from these units.

Today we’ve been warning everyone that the diabetes drug market is following this same path and every indicator tells us that this prediction is also coming true. The real question is can a company like Novo avoid the mistakes made by their BGM counterparts.

Can they, unlike their counterparts, adapt to this new environment, see realistically where this market is and more importantly where it is headed?  Their continued pursuit of Tresiba with the FDA and hiring even more reps tells Diabetic Investor that history will be repeating itself. That it won’t be long before that Novo also decides that it’s time to restructure and align costs with the new realities of this market.

We realize this not welcome news to all these new reps but it is unfortunately the way it is.

Source: Forbes Business

 
 

Don't miss ...

 

<a href="/latest_stories/all/all/30" rel="author">Forbes</a>
Forbes is among the most trusted resources for the world's business and investment leaders, providing them the uncompromising commentary, concise analysis, relevant tools and real-time reporting they need to succeed at work, profit from investing and have fun with the rewards of winning.

 

blog comments powered by Disqus

Latest stories

Hawkeye Technology Improves Time Clock Reporting and Payroll Integration in TimeClick LE 12
Logan, UT, April 18, 2014 --(PR.com)-- Hawkeye Technology, creator of TimeClick, a leading employee time clock software, announces the release of TimeClick version LE 12. This new version offers powerful new reporting...
 
 
Airbnb Cofounders Are Billionaires As Share Economy Leader Closes $450 Million Round At $10 Billion Valuation
It took a month, but Airbnb’s founders are confirmed as the share economy’s first billionaires, at least on paper. That’s because the home-sharing site has closed its new fundraising round, raising $450 million at a $10...
 
 
`Taxpayers Rely On IRS Guidance At Their Own Peril,' Tax Judge Rules
Before filing your 2013 tax return, did you  consult an Internal Revenue Service publication for clarification of some confusing point? That’s living dangerously. Or so a U.S.  Tax Court Judge declared this week. “...
 
 
Predicting The Most Expensive Games Of The 2014 NFL Schedule
Even at the times of little news during the offseason, the NFL keeps fans in anticipation of what might come next. With less than a month until the NFL Draft, the release of the 2014 NFL schedule is expected sooner. For...
 
 
 

Latest from the Network

Marisa Tomei is too old to play Lady Gaga?
Marisa Tomei thinks she's too old to play Lady Gaga in a movie. The 'The Wrestler' actress was flattered to hear the 'Applause' hitmaker would like her to play the 28-year-old singer if there is ever a film made about...
Read more on Celebrity Balla
 
Hawkeye Technology Improves Time Clock Reporting and Payroll Integration in TimeClick LE 12
Logan, UT, April 18, 2014 --(PR.com)-- Hawkeye Technology, creator of TimeClick, a leading employee time clock software, announces the release of TimeClick version LE 12. This new version offers powerful new reporting...
Read more on Business Balla
 
Airbnb Cofounders Are Billionaires As Share Economy Leader Closes $450 Million Round At $10 Billion Valuation
It took a month, but Airbnb’s founders are confirmed as the share economy’s first billionaires, at least on paper. That’s because the home-sharing site has closed its new fundraising round, raising $450 million at a $10...
Read more on Business Balla
 
`Taxpayers Rely On IRS Guidance At Their Own Peril,' Tax Judge Rules
Before filing your 2013 tax return, did you  consult an Internal Revenue Service publication for clarification of some confusing point? That’s living dangerously. Or so a U.S.  Tax Court Judge declared this week. “...
Read more on Business Balla
 
Predicting The Most Expensive Games Of The 2014 NFL Schedule
Even at the times of little news during the offseason, the NFL keeps fans in anticipation of what might come next. With less than a month until the NFL Draft, the release of the 2014 NFL schedule is expected sooner. For...
Read more on Business Balla
 
How The Wealthiest Families Make And Lose Their Money -- Part 5
In this series of articles on wealth creation and maintenance, we have hit on a few key findings of researchers and practitioners.  The vast majority of family wealth stems from business ownership and not inheritance. ...
Read more on Business Balla
 
Can High-Speed Internet Spark Better-Paying Jobs?
Many of us look at high-speed internet as a way to enjoy pleasures like clearer HDTV and speedier Wi-Fi. But as lightening-fast service gets rolled out in new markets, it could also pave the way to innovation–and new...
Read more on Business Balla
 
For NHL and NBA Playoffs, Parking, Like Tickets, Also Have A Premium
When the Nets and Raptors tip off tomorrow afternoon, the NBA playoffs will be underway.  Along with the NHL playoffs, many think the next two months are the most exciting in all of sports. Over the course of the next...
Read more on Business Balla
 
The Week Ahead: A Spring Breakout for the Economy?
Just a week ago the stock market was looking quite vulnerable as most of the major averages closed near their lows last Friday, April 11. There were signs of heavy selling, so I concluded last week that “On a short-term...
Read more on Business Balla
 
Which Teams Did The Best And Worst Job Of Pricing Tickets For The NHL Playoffs?
The Bruins have a long history of success with six Stanley Cups championships, most recently in 2010-11.  Heading into the 2014 NHL Playoffs, the Boston Bruinsare favored by Las Vegas to win their seventh.  While that’s...
Read more on Business Balla
 
 
Auto Balla Sexy Balla Sport Balla TV Balla Politics Balla Movie Balla Apple Balla Business Balla Ad Balla Celebrity Balla